{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:20:29Z","timestamp":1788294029174,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":70,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Michelle Hill, Medtronic"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Over one-third of Australian adults have hypertension, and this rate increases with age. Difficult-to-treat hypertension is high blood pressure that remains above target levels despite proper medicine adherence. This study explored the treatment experiences and goals of patients with severe difficult-to-treat hypertension to gain insights into renal denervation (RDN) as a therapeutic option.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Twelve Australian participants with severe difficult-to-treat hypertension were interviewed. Participants were recruited via a specialist recruitment company and specialist referral. Semi-structured interviews lasted about 60\u00a0min either online or by phone. Interviews were recorded and transcribed verbatim. Transcripts were analyzed using inductive and deductive thematic analysis in NVivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Participants had an average age of 65 years (range: 48\u201375 years), 58% identified as male and all lived across Australia, primarily in metropolitan areas (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20099; 75%). The average time since hypertension diagnosis was 22 years (range: 3\u201344 years) and nearly all participants had a family history of hypertension. Data analysis identified four themes regarding participants\u2019 experiences of living with severe difficult-to-treat hypertension and awareness of renal denervation therapy: (1) Diagnosis and monitoring of hypertension, (2) The impact of severe difficult-to-treat hypertension on quality of life, (3) The management of severe difficult-to-treat hypertension and (4) Awareness, perceptions and experiences with RDN.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides an in-depth understanding of the experiences of people living with severe difficult-to-treat hypertension and their treatment goals. It highlights the significant impact and stigma of living with severe difficult-to-treat hypertension, and the need to incorporate psychosocial support and patient education into the clinical management of this chronic condition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-026-06141-9","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:03:33Z","timestamp":1781841813000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Qualitative insights into the experiences and goals of people living with severe difficult-to-treat hypertension in Australia"],"prefix":"10.1186","volume":"26","author":[{"given":"Michelle","family":"Hill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenni","family":"Godsell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"6141_CR1","unstructured":"Australian Institute of Health and Welfare. Heart, stroke and vascular disease: Australian facts Canberra: Australian Government. 2024 [Available from: https:\/\/www.aihw.gov.au\/reports\/heart-stroke-vascular-diseases\/hsvd-facts\/contents\/risk-factors\/high-blood-pressure."},{"key":"6141_CR2","volume-title":"Guideline for the diagnosis and management of hypertension in adults","author":"National Heart Foundation of Australia","year":"2016","unstructured":"National Heart Foundation of Australia. Guideline for the diagnosis and management of hypertension in adults. Melbourne: National Heart Foundation of Australia; 2016."},{"key":"6141_CR3","unstructured":"Australian Bureau of Statistics. Hypertension and high measured blood pressure Canberra: ABS; 2023 [Available from: https:\/\/www.abs.gov.au\/statistics\/health\/health-conditions-and-risks\/hypertension-and-high-measured-blood-pressure\/latest-release."},{"issue":"4","key":"6141_CR4","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1161\/HYPERTENSIONAHA.122.20853","volume":"80","author":"G Sesa-Ashton","year":"2023","unstructured":"Sesa-Ashton G, Nolde JM, Muente I, Carnagarin R, Lee R, Macefield VG, et al. Catheter-Based Renal Denervation: 9-Year Follow-Up Data on Safety and Blood Pressure Reduction in Patients With Resistant Hypertension. Hypertension. 2023;80(4):811\u20139.","journal-title":"Hypertension"},{"issue":"10","key":"6141_CR5","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1161\/HYP.0000000000000240","volume":"81","author":"JL Cluett","year":"2024","unstructured":"Cluett JL, Blazek O, Brown AL, East C, Ferdinand KC, Fisher NDL, et al. Renal Denervation for the Treatment of Hypertension: A Scientific Statement From the American Heart Association. Hypertension. 2024;81(10):e135\u201348.","journal-title":"Hypertension"},{"issue":"6","key":"6141_CR6","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1161\/HYPERTENSIONAHA.108.189141","volume":"51","author":"DA Calhoun","year":"2008","unstructured":"Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment. Hypertension. 2008;51(6):1403\u201319.","journal-title":"Hypertension"},{"key":"6141_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1471-2288-9-47","volume":"9","author":"V Hagens","year":"2009","unstructured":"Hagens V, Dobrow MJ, Chafe R. Interviewee Transcript Review: assessing the impact on qualitative research. BMC Med Res Methodol. 2009;9:47.","journal-title":"BMC Med Res Methodol"},{"key":"6141_CR8","volume-title":"National Statement on Ethical Conduct in Human Research","author":"National Health and Medical Research Council AR, Council and Universities Australia","year":"2023","unstructured":"National Health and Medical Research Council AR, Council and Universities Australia. National Statement on Ethical Conduct in Human Research. Canberra: National Health and Medical Research Council; 2023."},{"key":"6141_CR9","unstructured":"Bellberry Limited. Levels of Ethical Review. 2025."},{"key":"6141_CR10","unstructured":"World Medical Association. WMA Declaration of Helsinki \u2013 Ethical Principles for Medical Research Involving Human Participants 2024 [Available from: https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki\/."},{"issue":"1","key":"6141_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1609406917733847","volume":"16","author":"LS Nowell","year":"2017","unstructured":"Nowell LS, Norris JM, White DE, Moules NJ. Thematic Analysis: Striving to Meet the Trustworthiness Criteria. Int J Qual Methods. 2017;16(1):1\u201313.","journal-title":"Int J Qual Methods"},{"issue":"2","key":"6141_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101.","journal-title":"Qual Res Psychol"},{"key":"6141_CR13","doi-asserted-by":"crossref","unstructured":"Nowell LS, Norris JM, White DE, Moules NJ. Thematic Analysis. Int J Qualitative Methods. 2017;16(1).","DOI":"10.1177\/1609406917733847"},{"issue":"6","key":"6141_CR14","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349\u201357.","journal-title":"Int J Qual Health Care"},{"key":"6141_CR15","unstructured":"Services Australia. Medicare Safety Nets: Australian Government. 2023 [Available from: https:\/\/www.servicesaustralia.gov.au\/medicare-safety-nets."},{"issue":"10","key":"6141_CR16","doi-asserted-by":"publisher","first-page":"e031773","DOI":"10.1136\/bmjopen-2019-031773","volume":"9","author":"M Perera","year":"2019","unstructured":"Perera M, de Silva CK, Tavajoh S, Kasturiratne A, Luke NV, Ediriweera DS, et al. Patient perspectives on hypertension management in health system of Sri Lanka: a qualitative study. BMJ Open. 2019;9(10):e031773.","journal-title":"BMJ Open"},{"issue":"652","key":"6141_CR17","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3399\/bjgp16X687757","volume":"66","author":"AK Goodhart","year":"2016","unstructured":"Goodhart AK. Hypertension from the patient\u2019s perspective. Br J Gen Pract. 2016;66(652):570.","journal-title":"Br J Gen Pract"},{"issue":"null","key":"6141_CR18","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.2147\/PPA.S429638","volume":"17","author":"S Malkon","year":"2023","unstructured":"Malkon S, Wettermark B, Kahan T, Bastholm-Rahmner P, Hasselstr\u00f6m J, Qvarnstr\u00f6m M. A Qualitative Study on Patients\u2019 Views on Hypertension and Antihypertensive Medications. Patient Prefer Adherence. 2023;17(null):3331\u20139.","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"6141_CR19","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41440-023-01492-8","volume":"47","author":"N Tomitani","year":"2024","unstructured":"Tomitani N, Hoshide S, Kario K. The importance of regular home blood pressure monitoring over the life course. Hypertens Res. 2024;47(2):540\u20132.","journal-title":"Hypertens Res"},{"issue":"2","key":"6141_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.15420\/ecr.2015.10.2.95","volume":"10","author":"J George","year":"2015","unstructured":"George J, MacDonald T. Home Blood Pressure Monitoring. Eur Cardiol. 2015;10(2):95\u2013101.","journal-title":"Eur Cardiol"},{"issue":"8","key":"6141_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11906-015-0578-5","volume":"17","author":"NW Carris","year":"2015","unstructured":"Carris NW, Smith SM. Quality of Life in Treatment-Resistant Hypertension. Curr Hypertens Rep. 2015;17(8):61.","journal-title":"Curr Hypertens Rep"},{"issue":"1","key":"6141_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40885-015-0028-3","volume":"21","author":"IA Kretchy","year":"2015","unstructured":"Kretchy IA, Owusu-Daaku FT, Danquah SA, Asampong E. A psychosocial perspective of medication side effects, experiences, coping approaches and implications for adherence in hypertension management. Clin Hypertens. 2015;21(1):19.","journal-title":"Clin Hypertens"},{"issue":"1","key":"6141_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12875-016-0428-9","volume":"17","author":"HM Johnson","year":"2016","unstructured":"Johnson HM, Warner RC, LaMantia JN, Bowers BJ. I have to live like I\u2019m old. Young adults\u2019 perspectives on managing hypertension: a multi-center qualitative study. BMC Fam Pract. 2016;17(1):31.","journal-title":"BMC Fam Pract"},{"issue":"12","key":"6141_CR24","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/j.cjco.2025.07.016","volume":"7","author":"KE Watson","year":"2025","unstructured":"Watson KE, Thomas IM, Patey AM, Robertshaw S, Moffat K, Tsuyuki RT, et al. A Qualitative Study Exploring Women\u2019s Understanding and Experiences of Managing Hypertension in Primary Care. CJC Open. 2025;7(12):1629\u201337.","journal-title":"CJC Open"},{"issue":"1","key":"6141_CR25","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1186\/s12889-021-11548-4","volume":"21","author":"B Bhandari","year":"2021","unstructured":"Bhandari B, Narasimhan P, Vaidya A, Subedi M, Jayasuriya R. Barriers and facilitators for treatment and control of high blood pressure among hypertensive patients in Kathmandu, Nepal: a qualitative study informed by COM-B model of behavior change. BMC Public Health. 2021;21(1):1524.","journal-title":"BMC Public Health"},{"key":"6141_CR26","doi-asserted-by":"publisher","first-page":"212560","DOI":"10.7573\/dic.212560","volume":"8","author":"MA Hameed","year":"2019","unstructured":"Hameed MA, Dasgupta I. Medication adherence and treatment-resistant hypertension: a review. Drugs Context. 2019;8:212560.","journal-title":"Drugs Context"},{"issue":"2","key":"6141_CR27","doi-asserted-by":"publisher","first-page":"e010035","DOI":"10.1136\/bmjopen-2015-010035","volume":"6","author":"MA Mohammed","year":"2016","unstructured":"Mohammed MA, Moles RJ, Chen TF. Medication-related burden and patients\u2019 lived experience with medicine: a systematic review and metasynthesis of qualitative studies. BMJ Open. 2016;6(2):e010035.","journal-title":"BMJ Open"},{"key":"6141_CR28","unstructured":"Medical Services Advisory Committee. 1659 \u2013 Catheter-based renal denervation for uncontrolled elevated systolic blood pressure: Department of Health and Aged Care. 2023 [Available from: https:\/\/www.msac.gov.au\/applications\/1659."},{"issue":"2","key":"6141_CR29","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41440-021-00760-9","volume":"45","author":"K Kario","year":"2022","unstructured":"Kario K, Kagitani H, Hayashi S, Hanamura S, Ozawa K, Kanegae H. A Japan nationwide web-based survey of patient preference for renal denervation for hypertension treatment. Hypertens Res. 2022;45(2):232\u201340.","journal-title":"Hypertens Res"},{"issue":"12","key":"6141_CR30","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s00392-019-01468-0","volume":"108","author":"RE Schmieder","year":"2019","unstructured":"Schmieder RE, H\u00f6gerl K, Jung S, Bramlage P, Veelken R, Ott C. Patient preference for therapies in hypertension: a cross-sectional survey of German patients. Clin Res Cardiol. 2019;108(12):1331\u201342.","journal-title":"Clin Res Cardiol"},{"issue":"1","key":"6141_CR31","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/HJH.0000000000002592","volume":"39","author":"RE Schmieder","year":"2021","unstructured":"Schmieder RE, Kandzari DE, Wang TD, Lee YH, Lazarus G, Pathak A. Differences in patient and physician perspectives on pharmaceutical therapy and renal denervation for the management of hypertension. J Hypertens. 2021;39(1):162\u20138.","journal-title":"J Hypertens"},{"key":"6141_CR32","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12)."},{"key":"6141_CR33","doi-asserted-by":"crossref","unstructured":"Schmieder RE, Mahfoud F, Mancia G, Azizi M, B\u00f6hm M, Dimitriadis K et al. European Society of Hypertension position paper on renal denervation 2021. J Hypertens. 2021;39(9).","DOI":"10.1097\/HJH.0000000000002933"},{"key":"6141_CR34","doi-asserted-by":"publisher","first-page":"114523","DOI":"10.1016\/j.socscimed.2021.114523","volume":"292","author":"M Hennink","year":"2022","unstructured":"Hennink M, Kaiser BN. Sample sizes for saturation in qualitative research: A systematic review of empirical tests. Soc Sci Med. 2022;292:114523.","journal-title":"Soc Sci Med"},{"issue":"4","key":"6141_CR35","first-page":"1173","volume":"16","author":"RJ Chenail","year":"2011","unstructured":"Chenail RJ. How to Conduct Clinical Qualitative Research on the Patient\u2019s Experience. Qualitative Rep. 2011;16(4):1173\u201390.","journal-title":"Qualitative Rep"},{"issue":"1","key":"6141_CR36","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1177\/0253717620977000","volume":"43","author":"C Andrade","year":"2021","unstructured":"Andrade C. The Inconvenient Truth About Convenience and Purposive Samples. Indian J Psychol Med. 2021;43(1):86\u20138.","journal-title":"Indian J Psychol Med"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-06141-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06141-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06141-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T02:08:54Z","timestamp":1787882934000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-06141-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6141"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-06141-9","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Formal ethics approval was not required for this study. The research was assessed as having a low level of risk and met the definition of negligible risk research, qualifying for exemption from ethical review, as defined in the National Statement on Ethical Conduct in Human Research Chap. 2.1 and Chap. 5.1.17. This meets the assessment requirements of Bellberry Human Research Ethics Committee.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MH is an employee of Medtronic Australasia. JG is an employee of CaPPRe, Australia. CaPPRe has consulted to AbbVie, Amgen, AstraZeneca, BMS, Celgene, CSL Behring, Edwards Lifesciences, Gilead, GSK, Ipsen, Janssen, Medtronic, Moderna, MSD, Novartis, Novo Nordisk, Roche, Sanofi, Sequiris, Takeda (Shire), UCB, and Vertex outside of the submitted work.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"752"}}